Aldeyra Therapeutics Inc to Host Research and Development Update Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Catherine Novack - Jonestrading Institutional Services LLC - Analyst : Just on Slide 17, what percent RASP binding is ideal? Are you looking for maximum binding? Or how should we think about what translates to efficacy here?

Question: Catherine Novack - Jonestrading Institutional Services LLC - Analyst : Then just a question on the manufacturing. Obviously, it's encouraging to see that these facilities pass inspections. Were there outstanding issues, can you remind us from previous NDA submissions? Were these facilities already inspected? How much of this is new update? How much was outstanding from prior NDA submissions?

Question: Yale Jen - Laidlaw & Company Uk Ltd - Analyst : Congrats on the progress. Just two questions here. The first one is that for the second-gen 246 and 248, what's the specific difference between

Question: Yale Jen - Laidlaw & Company Uk Ltd - Analyst : Maybe just to tag on this question answer here. You're talking about metabolized less rapidly. Have you guys reviewed the half-life of either 246 or 248?

Question: Yale Jen - Laidlaw & Company Uk Ltd - Analyst : Maybe the last question here really is that for the 248, you have a broad spectrum of sort of disease area you can tackle. You mentioned CNS today specifically as a new directions -- new expanded directions. How would you prioritize these different indications, atopic dermatitis and others over the next several quarters to see where you eventually place the bet in the more promising ones?